Analysis of corona vaccine safety in The Netherlands | Prof. Theo Schetters

The first hour of this video is a presentation by prof. Theo Schetters followed by a panel discussion. This is all in English. After that, there is a 30 minute interview in Dutch. Unfortunately, there are no subtitles available.

Theo Schetters studied biology at the University of Utrecht in the Netherlands. In 1980 he was employed by the Department of Immunology and the Veterinary Faculty of the University of Utrecht, where he has worked on the antigenic diversity of Trypanosoma parasites. From 1981 to 1987 he worked at the Department of Cytology and Histology at the University of Nijmegen in the Netherlands where he investigated immune susceptibility of mice to the Plasmodium berghei infection. In 1986 he obtained a PhD in Medicine from the University of Nijmegen in the Netherlands and received a visiting scientist award from the Royal Society (London) for working on malaria immunology at the National Institute for Medical Research in Mill Hill, London (GB) . From 1988 to 2014 he worked at Intervet International (Boxmeer, The Netherlands) where he developed a vaccine against Coccidiosis in chickens (Nobilis® Cox ATM) and also a vaccine against Babesia infections in dogs (Nobivac® Piro). He is the inventor of recombinant vaccines against Babesia divergence and Babesia Canis, and improved the vaccine formula against the Rhipicephalus tick. He is the founder of ProtActivity, a company that focuses on the development of vaccines against protozoan infections. He holds an Endowed Professor position in the Department of Veterinary Tropical Diseases, at the University of Pretoria, Pretoria, South Africa. He is a member of the editorial board of Veterinary Parasitology (Elsevier Publishers) and of Parasitology (Cambridge University Press). He has published more than 100 scientific articles (including book chapters) in international scientific journals.

SOURCE: https://odysee.com/@CafeWeltschmerz:f/Theo-Schetters,-lezing---interview